Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Evaluation of Genedrive® for Pathogen Detection

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.

Epistem Holdings Plc has announced that it has entered into a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University (Advanced Physics Laboratory), to undertake the combat evaluation of Epistem's Genedrive® handheld molecular device for pathogen detection.

The agreement will commence immediately and provides $0.6m (GBP 0.4m) over 5 months to develop and evaluate Genedrive® for the identification of three known disease pathogens.

Successful completion of the combat evaluation programme will secure ongoing investment for the development of Genedrive® as a handheld pathogen detection unit for the US Department of Defence.

Preparations for the 2014 launch of the company's first Genedrive® disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion.

Whilst unit testing is ongoing, preparations are being made for the commencement of final stage clinical trials in support of Indian regulatory approval.

2014 plans to undertake clinical trials with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to a potential WHO recommendation in 2015.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem, Global Health Investment Fund Sign Collaborative Funding Agreement
Agreement will see GHIF support the roll-out of Epistem's Genedrive® molecular diagnostic platform.
Wednesday, July 23, 2014
Epistem Announces Executive Board Appointments
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.
Monday, January 27, 2014
Epistem Tuberculosis Test Gains CE-IVD Registration
Epistem to place its TB test and Genedrive™ units for sale in the EEA member state markets.
Thursday, July 05, 2012
Epistem Signs Tuberculosis Channel Partner Agreement
Company signs sales and marketing agreement for rapid molecular test for TB.
Tuesday, March 06, 2012
Epistem Holdings Announce £2.8 Million Cash Placing
Company to use the net proceeds to accelerate the development and commercialization of Genedrive™.
Tuesday, November 29, 2011
Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!